Naturally occurringmonoclonal antibodies and their therapeutic potential for neurologic diseases

JAMA Neurology

Volumn 72, Issue 11, 2015, Pages 1346-1353

  Wootla, Bharath ^a   Watzlawik, Jens O ^a   Warrington, Arthur E ^a   Wittenberg, Nathan J ^b   Denic, Aleksandar ^a   Xu, Xiaohua ^a   Jordan, Luke R ^b   Papke, Louisa M ^a   Zoecklein, Laurie J ^a   Pierce, Mabel L ^a   Oh, Sang Hyun ^b   Kantarci, Orhun H ^a   Rodriguez, Moses ^a,c  

^a MAYO CLINIC   (United States)

^b University of Minnesota   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADUCANUMAB; ALZHEIMER DISEASE VACCINE; BAPINEUZUMAB; CALCIUM; MONOCLONAL ANTIBODY; NATALIZUMAB; PONEZUMAB; RECOMBINANT HUMAN MONOCLONAL IMMUNOGLOBULIN M 22; RILUZOLE; SOLANEZUMAB; UNCLASSIFIED DRUG; IMMUNOGLOBULIN CLASS; RECOMBINANT PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD BRAIN BARRIER; BRAIN INFECTION; BRAIN ISCHEMIA; CALCIUM TRANSPORT; COGNITION; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DRUG TARGETING; HUMAN; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NERVOUS SYSTEM INJURY; NEUROLOGIC DISEASE; NONHUMAN; OLIGODENDROGLIA; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMYELINIZATION; REVIEW; ANIMAL; IMMUNOLOGY; NERVOUS SYSTEM DISEASES;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN ISOTYPES; NERVOUS SYSTEM DISEASES; RECOMBINANT PROTEINS;

EID: 84946743031     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.2188     Document Type: Review

References (67)

1. Leslie M. Cleanup crew. Science. 2015;347(6226):1058-1059, 1061.
2. ClinicalTrials.gov. An Intravenous Infusion Study of rHIg M22 in PatientsWith Multiple Sclerosis. NCT01803867. http://1.usa.gov/1N2gsHJ. Accessed June 1, 2015.
3. Greenberg BM, Rodriguez M, Kantarci OH, et al. Safety and tolerability of the remyelinating therapeutic antibody rHIgM22 in patients with stable multiple sclerosis [poster P4.339/ACO P5130]. Poster presented at: 67th American Academy of Neurology Annual Meeting; April 18-25, 2015; Washington, DC.
4. Boyden SV. Natural antibodies and the immune response. Adv Immunol. 1966;5:1-28.
5. Avrameas S. Natural autoantibodies: from "horror autotoxicus" to "gnothi seauton. " Immunol Today. 1991;12(5):154-159.
6. Nguyen TT, Elsner RA, Baumgarth N. Natural IgM prevents autoimmunity by enforcing B cell central tolerance induction. J Immunol. 2015;194(4):1489-1502.
7. McQuaid S, Cunnea P, McMahon J, Fitzgerald U. The effects of blood-brain barrier disruption on glial cell function in multiple sclerosis. Biochem Soc Trans. 2009;37(pt 1):n329-331.
8. Gay D, Esiri M. Blood-brain barrier damage in acute multiple sclerosis plaques: an immunocytological study. Brain. 1991;114(Pt 1B):557-572.
9. Kwon EE, Prineas JW. Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions: an immunohistochemical study. J Neuropathol Exp Neurol. 1994;53(6):625-636.
10. Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE. Passage of amyloid β protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides. 2002;23(12):2223-2226.
11. Pepinsky RB, Shao Z, Ji B, et al. Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration. J Pharmacol Exp Ther. 2011;339(2):519-529.
12. Boado RJ, Lu JZ, Hui EK, Sumbria RK, Pardridge WM. Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor. Biotechnol Bioeng. 2013;110(5):1456-1465.
13. Watts RJ, Dennis MS. Bispecific antibodies for delivery into the brain. Curr Opin Chem Biol. 2013;17(3):393-399.
14. Couch JA, Yu YJ, Zhang Y, et al. Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci Transl Med. 2013;5(183):183ra57; 1-12.
15. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6(8):916-919.
16. De Mattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2001;98(15):8850-8855.
17. Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat Neurosci. 2002;5(5):452-457.
18. Bacskai BJ, Kajdasz ST, McLellan ME, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J Neurosci. 2002;22(18):7873-7878.
19. Morgan D. Immunotherapy for Alzheimer's disease. J Alzheimers Dis. 2006;9(3)(suppl):425-432.
20. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology. 2003;61(1):46-54.
21. Serrano-Pozo A, William CM, Ferrer I, et al. Beneficial effect of human anti-amyloid-β active immunization on neurite morphology and tau pathology. Brain. 2010;133(pt 5):1312-1327.
22. Boche D, Donald J, Love S, et al. Reduction of aggregated tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer's disease. Acta Neuropathol. 2010;120(1):13-20.
23. Blennow K, Zetterberg H, Rinne JO, et al; AAB-001 201/202 Investigators. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol. 2012;69(8):1002-1010.
24. Doody RS, Farlow M, Aisen PS; Alzheimer's Disease Cooperative Study Data Analysis and Publication Committee. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N Engl J Med. 2014;370(15):1460.
25. Doody RS, Thomas RG, Farlow M, et al; Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group. Phase 3 trials of solanezumab formild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370(4):311-321.
26. Burstein AH, Zhao Q, Ross J, et al. Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease. Clin Neuropharmacol. 2013;36(1):8-13.
27. Du Y, Dodel R, Hampel H, et al. Reduced levels of amyloid β-peptide antibody in Alzheimer disease. Neurology. 2001;57(5):801-805.
28. Szabo P, Relkin N, Weksler ME. Natural human antibodies to amyloid beta peptide. Autoimmun Rev. 2008;7(6):415-420.
29. O'Nuallain B, Hrncic R, Wall JS, Weiss DT, Solomon A. Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J Immunol. 2006;176(11):7071-7078.
30. Taguchi H, Planque S, Nishiyama Y, et al. Autoantibody-catalyzed hydrolysis of amyloid β peptide. J Biol Chem. 2008;283(8):4714-4722.
31. Nishiyama Y, Taguchi H, Hara M, Planque SA, Mitsuda Y, Paul S. Metal-dependent amyloid β-degrading catalytic antibody construct. J Biotechnol. 2014;180:17-22.
32. ClinicalTrials.gov. Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease. NCT01397539. http://j.mp/BIB037. Accessed June 30, 2015.
33. McKeith IG, Ballard CG, Perry RH, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology. 2000;54(5):1050-1058.
34. Papachroni KK, Ninkina N, Papapanagiotou A, et al. Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem. 2007;101(3):749-756.
35. Neff F, Wei X, Nolker C, Bacher M, Du Y, Dodel R. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun Rev. 2008;7(6):501-507.
36. Besong-Agbo D, Wolf E, Jessen F, et al. Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology. 2013;80(2):169-175.
37. Kantarci OH, Pirko I, Rodriguez M. Novel immunomodulatory approaches for the management of multiple sclerosis. Clin Pharmacol Ther. 2014;95(1):32-44.
38. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870-1880.
39. ClinicSpeak: natalizumab PML update. Q4 2014. BartsMS blog. http://bitly.com/nat-pml. Published January 30, 2015. Accessed June 1, 2015.
40. Novotna M, Paz Soldan MM, Abou Zeid N, et al. Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis [published online July 24, 2015]. Neurology. doi:10.1212/WNL.0000000000001856.
41. Lang W, Rodriguez M, Lennon VA, Lampert PW. Demyelination and remyelination in murine viral encephalomyelitis. Ann N Y Acad Sci. 1984;436:98-102.
42. Rodriguez M, Lennon VA, Benveniste EN, Merrill JE. Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. J Neuropathol Exp Neurol. 1987;46(1):84-95.
43. Mitsunaga Y, Ciric B, Van Keulen V, et al. Direct evidence that a human antibody derived from patient serum can promotemyelin repair in a mouse model of chronic-progressive demyelinating disease. FASEB J. 2002;16(10):1325-1327.
44. Warrington AE, Bieber AJ, Ciric B, Pease LR, Van Keulen V, Rodriguez M. A recombinant human IgMpromotesmyelin repair after a single, very low dose. J Neurosci Res. 2007;85(5):967-976.
45. Wittenberg NJ, Im H, Xu X, et al. High-affinity binding of remyelinating natural autoantibodies to myelin-mimicking lipid bilayers revealed by nanohole surface plasmon resonance. Anal Chem. 2012;84(14):6031-6039.
46. Paz Soldan MM, Warrington AE, Bieber AJ, et al. Remyelination-promoting antibodies activate distinct Ca2+ influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair. Mol Cell Neurosci. 2003;22(1):14-24.
47. Watzlawik J, Holicky E, Edberg DD, et al. Human remyelination promoting antibody inhibits apoptotic signaling and differentiation through Lyn kinase in primary rat oligodendrocytes. Glia. 2010;58(15):1782-1793.
48. Watzlawik JO, Warrington AE, Rodriguez M. PDGF is required for remyelination-promoting IgM stimulation of oligodendrocyte progenitor cell proliferation. PLoS One. 2013;8(2):e55149.
49. Pirko I, Ciric B, Gamez J, et al. A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS. FASEB J. 2004;18(13):1577-1579.
50. Filippi M, Rocca MA, Martino G, Horsfield MA, Comi G. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol. 1998;43(6):809-814.
51. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: pathogenetic and clinical implications. Brain. 1990;113(pt 5):1477-1489.
52. Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523(7560):337-341.
53. Aspelund A, Antila S, Proulx ST, et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med. 2015;212(7):991-999.
54. Barker CF, Billingham RE. Immunologically privileged sites. Adv Immunol. 1977;25:1-54.
55. Warrington AE, Bieber AJ, Van Keulen V, Ciric B, Pease LR, Rodriguez M. Neuron-binding human monoclonal antibodies support central nervous system neurite extension. J Neuropathol Exp Neurol. 2004;63(5):461-473.
56. Van Keulen VP, Ciric B, Radhakrishnan S, et al. Immunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12. Clin Exp Immunol. 2006;143(2):314-321.
57. Xu X, Warrington AE, Wright BR, et al. A human IgMsignals axon outgrowth: coupling lipid raft to microtubules. J Neurochem. 2011;119(1):100-112.
58. Xu X, Wittenberg NJ, Jordan LR, et al. A patterned recombinant human IgMguides neurite outgrowth of CNS neurons. Sci Rep. 2013;3:2267.
59. Denic A, Macura SI, Warrington AE, et al. A single dose of neuron-binding human monoclonal antibody improves spontaneous activity in a murine model of demyelination. PLoS One. 2011;6(10):e26001. doi:10.1371/journal.pone.0026001.
60. Wootla B, Denic A, Watzlawik JO, Warrington AE, Rodriguez M. A single dose of a neuron-binding human monoclonal antibody improves brainstem NAA concentrations, a biomarker for density of spinal cord axons, in a model of progressive multiple sclerosis. J Neuroinflammation. 2015;12(1):83.
61. Watzlawik JO, Kahoud RJ, Ng S, et al. Polysialic acid as an antigen for monoclonal antibody HIgM12 to treat multiple sclerosis and other neurodegenerative disorders. J Neurochem. 2015;134(5):865-878.
62. Gurney ME. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J Neurol Sci. 1997;152(suppl 1):S67-S73.
63. Cudkowicz ME, Katz J, Moore DH, et al. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11(3):259-265.
64. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2007;(1): CD001447.
65. Gros-Louis F, Soucy G, Lariviere R, Julien JP. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem. 2010;113(5):1188-1199.
66. Xu X, Denic A, Jordan LR, et al. A natural human IgMthat binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis. Dis Model Mech. 2015;8(8):831-842.
67. Absinta M, Sati P, Gaitan MI, et al. Seven-tesla phase imaging of acute multiple sclerosis lesions: a new window into the inflammatory process. Ann Neurol. 2013;74(5):669-678.